💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

There’s limited scientific evidence directly linking semaglutide use to vitamin B12 deficiency or recommending routine vitamin B12 supplementation for people taking semaglutide. Semaglutide is ...

Tirzepatide and semaglutide, while effective, are not cost-effective due to high prices, negating healthcare savings. Combining antiobesity medications with lifestyle modification improves health ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...